Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 4Gynecologic 3Lymphoid 2Sarcoma 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Recurrence 3Ovarian Neoplasms 3

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × chiauranib × Gynecologic × Clear all
NCT04921527 2024-10-18

CHIPRO

Chipscreen Biosciences, Ltd.

Phase 3 Recruiting
454 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03901118 2021-03-19

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Chipscreen Biosciences, Ltd.

Phase 2 Completed
47 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03166891 2020-01-18

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

Chipscreen Biosciences, Ltd.

Phase 1/2 Completed
25 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡